drugset / Trial / NCT01373242
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
Phase 1/2
Completed
54 enrolled
University of North Carolina, Chapel Hill
National Center for Complementary and Integrative Health (NCCIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study will be to increase the reaction threshold (desensitization) of peanut allergic children using peanut sublingual immunotherapy and to determine if the nonreactive state of the immune system persists after treatment has been discontinued (tolerance).
Timeline
- Start
- 2011-06
- Primary completion
- 2018-04-16
- Completion
- 2018-04-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liquid Peanut Extract | Protein / enzyme biologic | — | Other |